About: Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Further, it develops AMX0318, a GLP-1 receptor antagonist for the treatment of post-bariatric hypoglycemia and other rare diseaees. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Latest price: $26.28 (-4.21%)
AMLX NASDAQ Amylyx Pharmaceuticals Inc
Amylyx Pharmaceuticals Inc share price
AMLX price activity
Last Price
$26.280
Change (24hr)
-1.16 USD (-4.21%)
Volume
456.66K
Volume (4w avg)
-
Open
$27.01
Day Range
$26.06 - $27.27
Previous Close
$27.43
Last Trade
08 Oct, 3:21 pm GMT+0
Delayed
08 Oct, 3:21 pm GMT+0
AMLX price performance
Delayed
08 Oct, 3:21 pm GMT+0
AMLX Market Signals